Cellectar Biosciences, INC 8-K filings

Cellectar Biosciences has replaced its independent auditor, Baker Tilly, with Deloitte, effective for the fiscal year ending December 31, 2024.

Cellectar Biosciences has amended its lease agreement to include additional office space, extending the lease term and increasing its financial obligations.

Cellectar Biosciences' stockholders approved an amendment to the 2021 Stock Incentive Plan, increasing the number of shares reserved for issuance by 7,000,000.

Cellectar Biosciences reported positive topline data from its CLOVER WaM pivotal study and provided a corporate update along with its first quarter 2024 financial results.

Cellectar Biosciences reported positive topline data from its pivotal study of iopofosine I 131 in Waldenstrom's macroglobulinemia and provided a corporate update along with its 2023 financial results.

Cellectar Biosciences reports an updated share count as of January 31, 2024, following recent warrant exercises.

Cellectar Biosciences announced the full exercise of its Tranche A warrants from its September 2023 financing, resulting in gross proceeds of approximately $44.1 million.